Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lucentis (ranibizumab) is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
• This summary is based on the review of 46 systematic review(s)/meta-analysis(es). ^[1-46]
• Retinal Non-Perfusion (RNP) in Diabetic Retinopathy (DR): Anti-VEGF therapy (ranibizumab) may slow the progression of RNP compared with laser/sham at 12 months (SMD: -0.17; 95% CI: -0.29, -0.06) and 24 months (SMD: -0.21; 95% CI: -0.37, -0.05). Evidence certainty is low.
• Diabetic Macular Oedema (DMO): Brolucizumab 6 mg Q12W/Q8W was mostly comparable to aflibercept 2 mg and ranibizumab 0.5 mg regimens, with brolucizumab favored over ranibizumab 0.5 mg Q4W in various visual and anatomical outcomes.
• Polypoidal Choroidal Vasculopathy (PCV): Ranibizumab and aflibercept showed similar outcomes in BCVA and retinal thickness, with bevacizumab showing comparable results to ranibizumab. Brolucizumab was comparable to aflibercept in BCVA.
• Age-Related Macular Degeneration (AMD) with Retinal Pigment Epithelial Detachment (PED): Aflibercept was superior to ranibizumab in improving BCVA and reducing PED height.
• Ranibizumab showed no significant differences in adverse events, including ocular inflammatory events, compared to other anti-VEGF agents; however, an increased risk of intraocular pressure (IOP) elevation and cataract formation was observed with steroids compared to ranibizumab.
• No significant safety differences were noted between ranibizumab and laser therapy in preterm infants with retinopathy of prematurity (ROP), and similar outcomes were observed in terms of ocular adverse events among ranibizumab, bevacizumab, and aflibercept in age-related macular degeneration (AMD).
• Real-world studies of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) indicated no increased safety risks for ranibizumab, despite fewer injections and less pronounced visual gains compared to randomized controlled trials (RCTs).
• There is no population types or subgroups information available in the reviewed studies.